scholarly journals Differences in diagnosis, treatment, and survival rate of acute myeloid leukemia with or without disabilities: A national cohort study in the Republic of Korea

2020 ◽  
Vol 9 (15) ◽  
pp. 5335-5344
Author(s):  
Jihyun Kwon ◽  
So Young Kim ◽  
Kyoung Eun Yeob ◽  
Hye Sook Han ◽  
Ki Hyeong Lee ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Survival Rate ◽  
Myeloid Leukemia ◽  
Republic Of Korea ◽  
National Cohort ◽  
The Republic ◽  
Acute Myeloid

scholarly journals Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study

Leukemia ◽  
2021 ◽  
Author(s):  
Neel S. Bhatt ◽  
Malek J. Baassiri ◽  
Wei Liu ◽  
Nickhill Bhakta ◽  
Wassim Chemaitilly ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Myeloid Leukemia ◽  
Childhood Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Acute myeloid leukemia–induced remodeling of the human bone marrow niche predicts clinical outcome

2020 ◽  
Vol 4 (20) ◽  
pp. 5257-5268
Author(s):  
Yiyang Chen ◽  
Lina Marie Hoffmeister ◽  
Yasmin Zaun ◽  
Lucas Arnold ◽  
Kurt Werner Schmid ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Survival Rate ◽  
Clinical Outcome ◽  
Myeloid Leukemia ◽  
Bone Marrow Niche ◽  
Dependent Manner ◽  
Hematopoietic Stem ◽  
Acute Myeloid ◽  
First Diagnosis

Abstract Murine models of myeloid neoplasia show how leukemia infiltration alters the hematopoietic stem cell (HSC) niche to reinforce malignancy at the expense of healthy hematopoiesis. However, little is known about the bone marrow architecture in humans and its impact on clinical outcome. Here, we dissect the bone marrow niche in patients with acute myeloid leukemia (AML) at first diagnosis. We combined immunohistochemical stainings with global gene expression analyses from these AML patients and correlated them with clinical features. Mesenchymal stem and progenitor cells (MSPCs) lost quiescence and significantly expanded in the bone marrow of AML patients. Strikingly, their HSC- and niche-regulating capacities were impaired with significant inhibition of osteogenesis and bone formation in a cell contact–dependent manner through inhibition of cytoplasmic β-catenin. Assessment of bone metabolism by quantifying peripheral blood osteocalcin levels revealed 30% lower expression in AML patients at first diagnosis than in non-leukemic donors. Furthermore, patients with osteocalcin levels ≤11 ng/mL showed inferior overall survival with a 1-year survival rate of 38.7% whereas patients with higher osteocalcin levels reached a survival rate of 66.8%. These novel insights into the human AML bone marrow microenvironment help translate findings from preclinical models and detect new targets which might pave the way for niche-targeted therapies in AML patients.

Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.

1994 ◽  
Vol 12 (10) ◽  
pp. 2138-2145 ◽  
Author(s):  
P J Shaw ◽  
M E Bergin ◽  
M A Burgess ◽  
L Dalla Pozza ◽  
S J Kellie ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Bone Marrow Transplantation ◽  
Survival Rate ◽  
Complete Remission ◽  
Relapse Rate ◽  
Marrow Transplantation ◽  
Myeloid Leukemia ◽  
Free Survival ◽  
Acute Myeloid

PURPOSE To report the impact of bone marrow transplantation (BMT) with busulfan/cyclophosphamide (BuCy) as end consolidation in a cohort of consecutively diagnosed children with acute myeloid leukemia (AML). PATIENTS AND METHODS Between May 1987 and November 1992, 43 patients were diagnosed with AML. Tissue typing at diagnosis determined whether patients would proceed to autologous or allogeneic BMT as end consolidation after six cycles of chemotherapy. Conditioning for BMT was with BuCy, followed by allogeneic or unpurged autologous marrow infusion. RESULTS Of 37 patients who received chemotherapy, 35 achieved remission (95%) after one to six courses of treatment and 34 (92%) were transplanted. Five relapsed before BMT, four were subsequently transplanted in second complete remission (CR2) (n = 3) or untreated first relapse (n = 1), and one failed to respond to further therapy. All other patients proceeded to BMT in first complete remission (CR1). Eleven patients received allografts: one relapsed and one died of graft-versus-host disease (GvHD), for a leukemia-free survival rate of 90% at a median of 41 months after BMT (range, 3 to 60). For 23 autografts, there were two toxic deaths and eight relapses, with a leukemia-free survival rate of 61% at a median of 11 months after BMT (range, 0 to 66). The high relapse rate following autologous BMT led us to escalate the dose of Bu from 16 mg/kg to 600 mg/m2 using a single daily dose of Bu. CONCLUSION With modern supportive therapy, most newly diagnosed children with AML will enter remission and are eligible for intensification therapy. BuCy is well tolerated in children, which allowed us to escalate the dose of Bu in recent patients. Further follow-up is needed to determine whether this has an impact on the relapse rate following autologous BMT.

Characterization ofNPM1,FLT3, andIDH1mutations in adult patients with acute myeloid leukemia: a Brazilian cohort study

2016 ◽  
Vol 57 (12) ◽  
pp. 2901-2904
Author(s):  
Nathália Gomide Cruz ◽  
Ana Flávia Tibúrcio Ribeiro ◽  
Ana Beatriz Firmato Glória ◽  
Saman Abbas ◽  
Juliana Godoy Assumpção ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Myeloid Leukemia ◽  
Adult Patients ◽  
Brazilian Cohort ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document